Original researchA statistical analysis of the magnitude and composition of drug promotion in the United States in 1998
References (19)
Drug prescribing: A discussion of its variability and (ir) rationality
Health Policy
(1987)- et al.
Effects of promotion on pharmaceutical demand
Soc Sci Med
(1985) - et al.
Scientific versus commercial sources of influence on the prescribing behavior of physicians
Am J Med
(1982) Inequality aversion, health inequalities and health achievement
J Health Econ
(2002)Prescription Drug Expenditures in 2001: Another Year of Escalating Costs
(2002)- et al.
Factors related to errors in medication prescribing
JAMA
(1997) The role and value of pharmaceutical marketing
Arch Fam Med.
(1994)Persuasion or information? The economics of prescription drugs advertising
J Law Econ.
(1981)- et al.
Promotion of prescription drugs to consumers
N Engl J Med
(2002)
Cited by (49)
Does competition stimulate drug utilization? The impact of changes in market structure on US drug prices, marketing and utilization
2012, International Review of Law and EconomicsCitation Excerpt :Below we will attempt to assess how these two phenomena – free samples and therapeutic substitution – might cause the effect of expiration of a drug's patent on utilization of other drugs that treat the previously patent-protected drug's indication(s) to differ from its effect on the number of prescriptions for that drug dispensed by pharmacies. In 1998, free samples accounted for 52% of professional promotional expenditure (Ma, Stafford, Cockburn, & Finkelstein, 2003). As shown above, on average professional promotion expenditure declines by 60% between years 12 and 16 – when competition from generics rises rapidly – and there is a strong negative correlation across molecules between changes in generics’ market share and changes in professional promotion expenditure.
Drug sampling in dermatology
2012, Clinics in DermatologySecular trends in antibiotic consumption in the adult population in Emilia-Romagna, Italy, 2003-2009
2011, Clinical Microbiology and InfectionCitation Excerpt :The French per-capita investment would be equivalent, in Italy, to 10–30% of the cost of one single box of a common antibiotic. These amounts are much lower than those dedicated to promoting antibiotic use by the pharmaceutical companies, estimated to be about $5 per patient per year [29]. Finally, and probably most importantly, the reduction in antibiotic use has been associated with a reduction in antibiotic resistance [30].
Drug samples in dermatology: Special considerations and recommendations for the future
2010, Journal of the American Academy of DermatologySuitability and readability of consumer medical information accompanying prescription medication samples
2008, Patient Education and CounselingInternet marketing of neuroproducts: New practices and healthcare policy challenges
2007, Cambridge Quarterly of Healthcare Ethics